Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERASNYSEAMERICAN:LCTXOTCMKTS:NWBONASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.45+4.3%$1.37$1.01▼$3.45$393.77M1.091.75 million shs586,102 shsLCTXLineage Cell Therapeutics$1.08+12.6%$0.61$0.37▼$1.15$219.09M1.521.44 million shs4.68 million shsNWBONorthwest Biotherapeutics$0.26+0.2%$0.29$0.17▼$0.48$375.40M-1.092.05 million shs942,000 shsSANASana Biotechnology$2.97+14.2%$2.12$1.26▼$7.40$586.24M1.783.66 million shs5.76 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+4.32%+6.23%+18.85%-2.03%-32.87%LCTXLineage Cell Therapeutics+12.57%+25.82%+54.57%+115.96%+19.59%NWBONorthwest Biotherapeutics+0.16%-3.80%-6.58%+11.81%-43.70%SANASana Biotechnology+14.23%+5.69%+49.25%+64.09%-46.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca2.0742 of 5 stars3.50.00.00.01.12.51.3LCTXLineage Cell Therapeutics2.4508 of 5 stars3.51.00.00.01.83.30.6NWBONorthwest Biotherapeutics0.0688 of 5 stars0.02.00.00.01.50.00.0SANASana Biotechnology2.5904 of 5 stars3.50.00.00.03.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.57215.27% UpsideLCTXLineage Cell Therapeutics 3.00Buy$4.20288.89% UpsideNWBONorthwest Biotherapeutics 0.00N/AN/AN/ASANASana Biotechnology 3.00Buy$9.83231.09% UpsideCurrent Analyst Ratings BreakdownLatest LCTX, NWBO, ERAS, and SANA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025SANASana BiotechnologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.006/23/2025LCTXLineage Cell TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.006/23/2025LCTXLineage Cell TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/24/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/26/2025ERASErascaRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$1.50 per shareN/ALCTXLineage Cell Therapeutics$9.50M25.96N/AN/A$0.35 per share3.09NWBONorthwest Biotherapeutics$1.38M272.45N/AN/A($0.07) per share-3.69SANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)LCTXLineage Cell Therapeutics-$18.61M-$0.12N/AN/AN/A-169.57%-22.64%-15.27%8/6/2025 (Estimated)NWBONorthwest Biotherapeutics-$83.78M-$0.07N/A∞N/A-5,757.57%N/A-303.49%8/7/2025 (Estimated)SANASana Biotechnology-$266.76M-$0.88N/AN/AN/AN/A-86.58%-44.49%8/6/2025 (Estimated)Latest LCTX, NWBO, ERAS, and SANA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025NWBONorthwest BiotherapeuticsN/A-$0.01N/A-$0.01N/A$0.38 million5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/8/2025Q1 2025SANASana Biotechnology-$0.22-$0.20+$0.02-$0.21N/AN/A3/31/2025Q4 2024NWBONorthwest BiotherapeuticsN/A-$0.02N/A-$0.02N/A$0.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/ALCTXLineage Cell TherapeuticsN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A12.3512.35LCTXLineage Cell TherapeuticsN/A3.823.82NWBONorthwest BiotherapeuticsN/A0.060.06SANASana BiotechnologyN/A3.403.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%LCTXLineage Cell Therapeutics62.47%NWBONorthwest Biotherapeutics0.04%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipERASErasca14.40%LCTXLineage Cell Therapeutics26.80%NWBONorthwest Biotherapeutics8.70%SANASana Biotechnology31.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.29 million242.49 millionOptionableLCTXLineage Cell Therapeutics60228.36 million167.16 millionNot OptionableNWBONorthwest Biotherapeutics201.46 billion1.33 billionNot OptionableSANASana Biotechnology380225.48 million155.35 millionOptionableLCTX, NWBO, ERAS, and SANA HeadlinesRecent News About These CompaniesSana Biotechnology, Inc. (NASDAQ:SANA) Receives $10.80 Consensus Price Target from BrokeragesJune 25 at 1:13 AM | americanbankingnews.comBofA Remains Bullish on Sana Biotechnology (SANA)June 24 at 4:18 PM | insidermonkey.comSana Biotechnology (NASDAQ:SANA) Given Market Outperform Rating at JMP SecuritiesJune 24 at 9:54 AM | marketbeat.comSana Biotechnology (NASDAQ:SANA) Stock Price Up 17.2% - Should You Buy?June 23 at 1:11 PM | marketbeat.comSana Biotechnology stock soars after positive diabetes treatment resultsJune 23 at 12:33 PM | investing.comTwo Biotech Stocks Poised For Big Moves On MondayJune 23 at 12:33 PM | benzinga.comSana Biotechnology Shares Climb on Positive Diabetes Study ResultsJune 23 at 12:33 PM | marketwatch.comSana Biotechnology Reports Promising Six-Month Results from First-in-Human Study on Hypoimmune-Modified Pancreatic Islet Cell Transplant for Type 1 DiabetesJune 23 at 10:46 AM | quiverquant.comSana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without ImmunosuppressionJune 23 at 10:05 AM | globenewswire.comSana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 22 at 4:05 AM | marketbeat.comSana Biotechnology, Inc. (NASDAQ:SANA) Shares Acquired by Clarius Group LLCJune 20, 2025 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Stock Price Up 7.3% - Still a Buy?June 17, 2025 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Trading Down 7.2% - Here's WhyJune 11, 2025 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Shares Up 8.3% - What's Next?June 10, 2025 | marketbeat.comSana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific SessionsJune 9, 2025 | globenewswire.comTwo Sigma Investments LP Grows Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)June 8, 2025 | marketbeat.comBiggest Stocks in NASDAQ Featuring Sana Biotechnology and KalkineJune 7, 2025 | kalkinemedia.comSana Biotechnology, Inc. (NASDAQ:SANA) Stock Position Raised by Two Sigma Advisers LPJune 6, 2025 | marketbeat.comSana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Millennium Management LLCJune 5, 2025 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Trading Up 10.9% - Time to Buy?June 4, 2025 | marketbeat.comBank of America Corp DE Increases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)June 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCTX, NWBO, ERAS, and SANA Company DescriptionsErasca NASDAQ:ERAS$1.45 +0.06 (+4.32%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 06/24/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Lineage Cell Therapeutics NYSEAMERICAN:LCTX$1.08 +0.12 (+12.57%) Closing price 06/24/2025 04:10 PM EasternExtended Trading$1.10 +0.02 (+1.85%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.Northwest Biotherapeutics OTCMKTS:NWBO$0.26 +0.00 (+0.16%) As of 06/24/2025 03:56 PM EasternNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Sana Biotechnology NASDAQ:SANA$2.97 +0.37 (+14.23%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$2.97 0.00 (0.00%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
